不同治疗方式对巴塞罗那分期B期HCC患者疗效及预后影响因素  

The Factor of efficacy and prognosis of different stages of treatment for Barcelona B in patients with HCC

作　　者：鲁号锋 黄强[1] 李宓[1] 刘建平[1] 邵成泽 

机构地区：[1]湖北省荆州市第一人民医院肝胆外科二病区,荆州434000 [2]湖北省荆州市肿瘤医院肿瘤外科,荆州434000

出　　处：《肝胆外科杂志》2015年第1期51-53,共3页Journal of Hepatobiliary Surgery

摘　　要：目的探讨肝切除手术与经肝动脉导管化疗栓塞(TACE)治疗巴塞罗那分期(BCLC)B期肝细胞癌(HCC)患者的疗效及影响患者预后的危险因素。方法选取168例BCLC B期HCC患者为研究对象,根据患者治疗方式分为手术组86例以及TACE组82例,对比分析两组治疗效果。术后对两组患者随访5年,应单因素及Logistic多因素分析影响BCLC B期HCC患者预后的危险因素。结果肝切除术组术后1、3、5年总生存率及无复发生存率分别为90.70%、48.84%、37.21%及32.56%,TACE组术后1、3、5年总生存率及无复发生存率分别为75.61%、29.77%、12.19%及2.44%。经Cox风险模型分析可知,TACE术、肿瘤直径、肿瘤数目是影响BCLC B期HCC患者生存率的危险因素,而无复发是BCLC B期HCC患者生存率的保护因素。结论肝切除术治疗BCLC B期HCC患者疗效较TACE显著,可有效提高后患者总生存率及无复发生存率。Objective To investigate the factor of efficacy and prognosis of liver resection and hepatic arterial chemoembolization （TACE） therapy for Barcelona staging （BCLC） B of hepatocellular carcinoma （HCC）. Methods 168 cases of BCLC B of HCC patients were diveced into surgical treatment group （ n = 86） and TACE group （ n = 82 ）. The treatment effect of two groups were comparated. Two groups of patients were followed up, The risk factors of BCLC B HCC prognosis were analyzed with logistic univariate and multivariate analysis. Results The 1,3,5-year overall survival and recurrence-free survival rates of prognosis of liver resection were 90. 70%, 48.84%, 37. 21% and 32. 56% and TACE group were 75.61%, 29.77%, 12. 19% and 2. 44%. The model analysis shows, TACE surgery, tumor size, number of tumors were the risk factors BCLC B survival of HCC patients with cox risk model analysis and relapse was protective factor BCLC B survival of patients with HCC. Conclusion Liver resection of HCC BCLC B patients compared the efficacy of TACE significantly, can effectively improve patient after recurrence-free survival and overall survival.

关 键 词：肝切除手术 经肝动脉导管化疗栓塞 肝细胞癌 预后 

分 类 号：R735.7[医药卫生—肿瘤]